Article | December 11, 2023

A Tale Of Two Brothers: The Abpro Founders

Source: Cytiva

For brothers and biotech co-founders Ian Chan, MBA, and Eugene Chan, M.D., designing powerful antibody therapeutics is both a personal and global imperative. While brainstorming their latest entrepreneurial pursuit, the Chan brothers recognized the critical benefits of antibodies for creating targeted, non-toxic therapies. To produce them faster and tackle more targets, the brothers built DiversImmune®, a platform that could generate antibodies for traditionally difficult targets at industry-leading speeds. The company borne of this mission, Abpro, now leverages DiversImmune® to develop antibody therapeutics to treat blockbuster indications like breast cancer and COVID-19.

The Chans credit their success to the power of antibodies as natural, safe, and effective mechanisms for fighting disease. Thanks to their business and science acumen, the brothers have built a compelling model that has earned support and recognition across the industry. More important to them, however, is that they are rapidly developing effective antibody therapeutics that will offer hope and health to patients around the world — including their own mother. Download the full article to read more about what the Chan brothers are creating with Abpro.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Biosimilar Development? Subscribe today.

Subscribe to Biosimilar Development X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Biosimilar Development